Sun Pharmaceuticals reported an overall net profit of 1,984 crore for Q4FY23 on May 26. This is an improvement from the 2,277 crore net loss reported for the same period in FY22. EBITDA for the firm for the Q4 was Rs.2,803 crore while operating revenue stood at Rs. 10,930.6 crore.
For Q4FY23, sales of US formulations were $430 million, up 10.5% from Q4 FY22, and represented for around 33.0% of total consolidated sales. For FY23, sales of formulations in EM were $983 million, an increase of 8.6 percent from the prior-year period.
For Q4FY23 EM sales were $221 million- up 7.5% from Q4 FY22 and accounted for around 17% of total consolidated sales. External API sales for Sun Pharma in FY23 stood at Rs.1972.4 crore, an increase of 7.5% compared to the prior-year period. With a Q4FY23 total of Rs. 385.2 crore API exports were 6.9% lower than in the same period in FY22.
Subject to shareholder approval, the board of directors has proposed its dividend of Rs. 4 for equity share of Re. 1 each. The total dividend for FY23 is Rs. 11.5 per share, up from Rs. 10 per share in FY22.
Sun Pharma’s stock was 3.02 percent higher at 973.25 at 3:15 pm on the BSE.